Medicalgorithmics, a Warsaw Stock Exchange-listed developer of innovative cardiology technologies, is entering a talks with a global, multi-billion-dollar MedTech player—
a company operating in the U.S. and international markets and listed on the New York Stock Exchange. The talks focus on potential collaboration between the two entities regarding the aforementioned company’s use of Medicalgorithmics’ proprietary AI-based technologies in the field of ambulatory cardiac diagnostics. The talks were initiated after the parties signed a mutual non-disclosure agreement (NDA).
The scope of cooperation under consideration includes both retrospective ECG analysis services and Mobile Cardiac Telemetry (MCT) solutions, which enable patient monitoring and the detection of cardiac arrhythmias in near real time.
– The company with which we are beginning talks is one of the largest global companies in the MedTech sector, listed on the New York Stock Exchange. This is a tremendous honor for Medicalgorithmics and our technologies, particularly DRAI and DRP. We have many hours of negotiations and a lot of work ahead of us to ensure the talks are successful. Companies like this giant are distinguished by their particular attention to the quality of the solutions they offer, and that is exactly what we offer. “Our AI technology demonstrated high clinical efficacy in the independent DRAI Martini study, the results of which were published in early 2025 in Nature Medicine, one of the most prestigious medical journals in the world – comments Dr. Kris Siemionow, CEO of Medicalgorithmics.
As part of the next stage of negotiations, the parties will proceed with in-depth technological and operational testing. The goal will be to verify the potential for integrating Medicalgorithmics’ proprietary solutions with the current diagnostic offerings of the aforementioned MedTech company.
The initiation of these talks stems from the growing market demand for Medicalgorithmics’ innovative technologies and is part of the Company’s growth strategy, which aims to strengthen relationships with key players in the medical sector in the U.S. and on global markets.
– A potential partnership with such a major player would be another step in our expansion into the U.S. market. Last year, we began a partnership with one of the top five largest IDTFs in the U.S., which resulted, among other things, in us exceeding quarterly EBITDA profitability and reaching operational cash break-even. The U.S. is the largest medical market in the world, which is why our presence there and our growth are a priority, – adds dr Kris Siemionow.
At this stage, there is no guarantee that the talks will result in a legally binding commercial agreement. The company will provide updates on any significant developments related to the process, in accordance with disclosure requirements.